Prognostic value of RT-PCR tyrosinase detection in peripheral blood of melanoma patients
Metadatos
Mostrar el registro completo del ítemAutor
Carrillo Delgado, Esmeralda Esperanza; Prados Salazar, José Carlos; Marchal Corrales, Juan Antonio; Boulaiz Tassi, Houria; Martínez, Antonio; Rodríguez Serrano, Fernando; Caba Pérez, Octavio; Serrano Ortega, Salvio; Aránega Jiménez, AntoniaEditorial
Hindawi Publishing Corporation; IOS Press
Materia
Polymerase chain reaction Circulating tumor cells Messenger RNA Reverse transcriptase Melanoma Cutaneous melanoma Residual disease Clinical stage Reaction assay Marker
Fecha
2006Referencia bibliográfica
Carrillo, E.; et al. Prognostic value of RT-PCR tyrosinase detection in peripheral blood of melanoma patients. Disease Markers, 22(3): 175-181 (2006). [http://hdl.handle.net/10481/32689]
Patrocinador
This study was supported by the Fondo de Investigación Sanitaria de la Seguridad Social (FIS), Spain through no. PI041372.Resumen
Malignant melanoma (MM) prognosis has been related to tumour thickness and clinical stage and metastasis risk has been associated with presence of tumour cells in peripheral blood. The aim of this study was to determine the relationship between presence of tyrosinase in peripheral blood of MM patients and their clinical prognosis. Blood samples from 58 MM patients (stage I–IV) were analysed, using RT-PCR assay to detect tyrosinase mRNA. The results showed that positive RT-PCR assay for tyrosinase were significantly associated with clinical status and tumour thickness. After a median follow-up of 24 months, RT-PCR results were found to be significant correlated with recurrence (p < 0.05) and clinical stage III (p < 0.05). Separate analysis of stage III tumours to determine the prognostic value of tyrosinase presence in peripheral blood showed an overall 24-month survival rate of 70% in the RT-PCR negative group versus 10% in the positive group (p < 0.02). These results suggest that detection of circulating melanoma cells may be especially relevant in stage III patients, in whom RT-PCR positivity defines a subpopulation at high risk of recurrence.